LABCORP HOLDINGS INC.
LHAPI behind this page
LH Q1 2026 request
Playground key active
/api/financials?ticker=LH&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 3,537.6 | 3,345.1 | +5.8% |
Show Business Segments breakouts |
|||
| Biopharma Laboratory Services · Operating Segments | 780.6 | 721.3 | +8.2% |
| Diagnostics · Operating Segments | 2,762.1 | 2,629.6 | +5.0% |
Show Geography breakouts |
|||
| US | 2,914 | 2,813.8 | +3.6% |
Show Consolidation Items breakouts |
|||
| Intersegment Elimination | 5.1 | 5.8 | -12.1% |
| Cost of Revenue | 2,523.8 | 2,397.1 | +5.3% |
| Gross Profit | 1,013.8 | 948 | +6.9% |
| Selling, General & Administrative | 551 | 546 | +0.9% |
| Amortization Of Intangible Assets | 75.6 | 69.6 | +8.6% |
| Net Restructuring And Other Special Charges | 6.4 | 6.4 | 0.0% |
| Operating Income | 380.8 | 326 | +16.8% |
Show Business Segments breakouts |
|||
| Biopharma Laboratory Services · Operating Segments | 120.7 | 106.9 | +12.9% |
| Corporate | -116.6 | -132.4 | +11.9% |
| Diagnostics · Operating Segments | 458.7 | 427.5 | +7.3% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 579.4 | 534.4 | +8.4% |
| Interest Expense | -55.1 | -56 | +1.6% |
| Investment Income Net | 12.2 | 6.5 | +87.7% |
| Income Loss From Equity Method Investments | -5.1 | -0.3 | -1600.0% |
| Other Non-Operating Income (Expense) | -13.1 | -1 | -1210.0% |
| Income Lossfrom Continuing Operations Before Income Taxesand Noncontrolling Interest | 319.7 | 275.2 | +16.2% |
| Income Tax Expense (Benefit) | 41.7 | 62.2 | -33.0% |
| Net Income | 278 | 213 | +30.5% |
| Net Income Loss Attributable To Noncontrolling Interest | -0.2 | -0.2 | 0.0% |
| Net Income | 277.8 | 212.8 | +30.5% |
Show Equity Components breakouts |
|||
| Retained Earnings | 277.8 | 212.8 | +30.5% |
| EPS (Basic) | 3.37 | 2.54 | +32.7% |
| EPS (Diluted) | 3.35 | 2.52 | +32.9% |
| Comprehensive Income | 242.2 | 282.8 | -14.4% |
| Wtd Avg Shares (Basic) | 82.3 | 83.6 | -1.6% |
| Wtd Avg Shares (Diluted) | 82.9 | 84.3 | -1.7% |
| Labor And Related Expense (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Biopharma Laboratory Services | 309.3 | 289.7 | +6.8% |
| Diagnostics | 1,188.1 | 1,123.6 | +5.7% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 981.1 | 369.4 | +165.6% |
| Accounts Receivable | 2,288.6 | 2,123.2 | +7.8% |
| Unbilled Contracts Receivable | 161.9 | 151.3 | +7.0% |
| Inventory | 497.7 | 488.3 | +1.9% |
| Prepaid Expenses & Other Current Assets | 629.5 | — | — |
| Total Current Assets | 4,558.8 | 3,789.7 | +20.3% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 3,065.5 | 3,090.8 | -0.8% |
| Goodwill | 6,955.2 | 6,421.1 | +8.3% |
Show Business Segments breakouts |
|||
| Biopharma Laboratory Services | 1,345.7 | — | — |
| Diagnostics | 5,609.5 | — | — |
| Other Non-Current Assets | 724.9 | 647 | +12.0% |
| Total Assets | 19,087.1 | 17,603.8 | +8.4% |
| Intangible Assets | 3,083.5 | 2,929.7 | +5.2% |
Show Schedule Of Other Intangible Assets By Major Class [Axis] breakouts |
|||
| Customer Relationships | 2,765.1 | 2,582.3 | +7.1% |
| Noncompete Agreements | 106.6 | 96.6 | +10.4% |
| Other Intangible Assets | 9.5 | 16.7 | -43.1% |
| Patents, Licenses And Technology [Member] | 202.3 | 234.1 | -13.6% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 3,636.1 | 3,487.2 | +4.3% |
| Investments In Affiliates Subsidiaries Associates And Joint Ventures | 146.6 | 168 | -12.7% |
| Current Liabilities | |||
| Accounts Payable | 695.7 | 717.9 | -3.1% |
| Accrued Liabilities | 851.9 | 770.4 | +10.6% |
| Deferred Revenue | 405.2 | 388.3 | +4.4% |
| Operating Lease Liability Current | 183.2 | 182.8 | +0.2% |
| Finance Lease Liability Current | 4.6 | 4.8 | -4.2% |
| Current Portion of Long-Term Debt | 500.4 | — | — |
| Total Current Liabilities | 2,641 | 2,064.6 | +27.9% |
| Non-Current Liabilities | |||
| Long-Term Debt | 5,833.7 | 5,568.7 | +4.8% |
| Operating Lease Liabilities | 656.5 | 696.4 | -5.7% |
| Finance Lease Liability Noncurrent | 62.2 | 66.5 | -6.5% |
| Deferred Income Taxes And Other Tax Liabilities Noncurrent | 456.4 | — | — |
| Other Non-Current Liabilities | 691.8 | 497.9 | +38.9% |
| Total Liabilities | 10,341.6 | 9,282.1 | +11.4% |
| Other Liabilities | |||
| Noncontrolling Interest Mezzanine Equity | 16.9 | 14.3 | +18.2% |
| Stockholders' Equity | |||
| Common Stock | 7.4 | 7.6 | -2.6% |
| Retained Earnings | -8,784.4 | — | — |
| Accumulated Other Comprehensive Income | -63.2 | -191.6 | +67.0% |
| Total Stockholders' Equity | 8,728.6 | 8,307.4 | +5.1% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -63.2 | -191.6 | +67.0% |
| Common Stock | 7.4 | 7.6 | -2.6% |
| Retained Earnings | 8,784.4 | 8,455.6 | +3.9% |
| Total Liabilities & Equity | 19,087.1 | 17,603.8 | +8.4% |
| Common Stock Shares Issued Not Disclosed | 82.3 | — | — |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 173.3 | 166.8 | +3.9% |
| Stock-Based Compensation | 31.7 | 32.8 | -3.4% |
| Operating Lease Right Of Use Asset Amortization Expense | 48 | 48.6 | -1.2% |
| Increase Decrease In Deferred Income Taxes | 2 | -6.1 | +132.8% |
| Other Operating Activities Cash Flow Statement | 11.4 | 8.1 | +40.7% |
| Change in Accounts Receivable | -187.9 | -170.8 | -10.0% |
| Increase Decrease In Contract With Customer Asset | -6.2 | 3.9 | -259.0% |
| Change in Inventory | 35.4 | 8.4 | +321.4% |
| Change in Prepaid & Other Assets | 4 | 45 | -91.1% |
| Change in Accounts Payable | -138.7 | -147.6 | +6.0% |
| Increase Decrease In Deferred Revenue | -32.1 | -8.9 | -260.7% |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -27.4 | -174.7 | +84.3% |
| Net Cash from Operations | 191.5 | 18.5 | +935.1% |
| Investing Activities | |||
| Capital Expenditures | -121 | -126 | +4.0% |
| Proceeds From Sale Of Property Plant And Equipment | 7.8 | 0.5 | +1460.0% |
| Payments To Acquire Investments | -6.7 | -157 | +95.7% |
| Payments To Acquire Businesses Net Of Cash Acquired | -202.2 | -53.5 | -277.9% |
Show Business Acquisition breakouts |
|||
| Parkview Health Systems, Inc. [Member] | -165 | — | — |
| Net Cash from Investing | -322.1 | -336 | +4.1% |
| Financing Activities | |||
| Proceeds From Other Debt | 750 | — | — |
| Tax Withholding for Share Compensation | -39.8 | -25.5 | -56.1% |
| Net Proceeds From Issuance Of Stock To Employees | 32.9 | 25.7 | +28.0% |
| Payments Of Dividends | -61.2 | -61.6 | +0.6% |
| Share Repurchases | -98 | — | — |
| Proceeds From Payments For Other Financing Activities | -3.4 | -3.3 | -3.0% |
| Net Cash from Financing | 580.5 | -839.7 | +169.1% |
| Supplemental | |||
| Income Taxes Paid | 13.1 | 20.3 | -35.5% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | -1.1 | 7.9 | -113.9% |
| Net Change in Cash | 448.8 | -1,149.3 | +139.0% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.